Zydus Takes Aim At Three Rivers’ Hep C Patent

Law360, New York (May 18, 2007, 12:00 AM EDT) -- Generic drug company Zydus Pharmaceuticals USA Inc. has shot back at drug maker Three Rivers Pharmaceuticals LLC, asserting that its ribavirin caplets and tablets do not infringe Three Rivers’ patent for its hepatitis C drug.

Zydus filed a response Thursday to the suit Three Rivers filed in April in the U.S. District Court for the Eastern District of Virginia, seeking declaratory judgment that Three Rivers’ patent is invalid and unenforceable.

The patent covers a method for producing ribavirin pellets, which Three Rivers markets and sells under...
To view the full article, register now.